Form 4: Mereo BioPharma Director Jacquet Pierre Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Director Pierre Jacquet reports acquisition and disposal of derivative securities in Mereo BioPharma Group plc.
Summary
- On February 5, 2025, Director Pierre Jacquet reported changes in beneficial ownership of Mereo BioPharma Group plc securities.
- Jacquet acquired 55,000 share options with an exercise price of $3.16, vesting monthly over one year and expiring on February 5, 2035.
- Jacquet also acquired 15,243 deferred restricted stock units (DRSUs), which will be paid in American Depositary Shares (ADSs) after separation of service.
- Each ADS represents five ordinary shares of the Issuer.
- Jacquet disposed of 55,000 share options and 15,243 deferred restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is a common practice for publicly traded companies.
Stakeholder Impact
- The changes in ownership may be of interest to shareholders, but the impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of transaction for share options and deferred restricted stock units. |
| 02/05/2025 | Grant date for share options, vesting monthly over one year. |
| 02/05/2035 | Expiration date for share options. |
| 02/06/2025 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.